Whole-brain, cellular-resolution imaging reveals a hierarchical thalamus–brainstem attractor network that encodes recent history and shapes behavioural bias in zebrafish.
Category: neuroscience – Page 78
Brain tumor map finds immune cell states that may predict meningioma recurrence
One of the most detailed maps to date of meningioma—the most common brain tumor in adults—reveals how the tumor’s surrounding environment helps drive disease behavior and patient outcomes, according to new research from Mayo Clinic.
The study, published in Nature Genetics and conducted in collaboration with scientists at Princess Margaret Cancer Center in Toronto, combines several advanced laboratory techniques to examine tumors at an unprecedented level of detail, offering clues to why some meningiomas grow slowly while others recur or become more aggressive. The findings could lead to more precise ways to predict risk and guide treatment decisions.
Growing evidence suggests that traditional grading systems for meningioma do not fully capture the behavior of these complex tumors, prompting the development of molecular classification tools that more accurately predict which tumors are more likely to recur after surgery.
Parkinson’s medication shows promise in treating treatment-resistant depression
For many people who suffer from depression, the condition is not just about feeling down but also about a loss of motivation and difficulty finding pleasure in activities they used to enjoy. A new study conducted in Sweden shows that a medicine used to treat Parkinson’s disease can be used as an add-on therapy to alleviate these symptoms in some patients with treatment-resistant depression. The study has been published in Nature Medicine.
The researchers at Lund University and the psychiatric services in Region Skåne have identified the potential new therapy for the condition associated with depression that involves a reduced ability to feel joy, pleasure or motivation—known as anhedonia. Those affected may lose interest in things that they previously found meaningful or rewarding.
The study is an example of what is known as drug repurposing, whereby an already approved medicine is used to treat a different condition. In this study, the researchers investigated pramipexole, which has long been used to treat Parkinson’s disease, as an add-on therapy for depression with marked anhedonia.
Popular joint pain supplement might increase Alzheimer’s risk, study says
A popular over-the-counter supplement taken for joint pain might increase people’s risk for Alzheimer’s disease, a new study says.
Glucosamine use is associated with a 25% higher odds that a person will progress from mild cognitive impairment to dementia and Alzheimer’s disease, researchers report in the journal Nature Metabolism.
“While it’s an association and not proof of causality, it does raise an important clinical question that now deserves much more attention,” researcher Matt Gentry said in a news release. He’s chair of biochemistry and molecular biology at the University of Florida.
Hyperglycosylation is a metabolic driver of Alzheimer’s disease
Through spatial multiomics, spatial stable isotope tracing and retrospective cohort analyses, this study identifies hyperglycosylation as a driver of Alzheimer’s disease and a promising therapeutic target.
Faulty protein cleanup gene tied to severe early-onset neurological disorders
Though protein clumps associated with Alzheimer’s and Parkinson’s were discovered more than a century ago, researchers remain largely unable to prevent them from forming or eliminate them from the brain. And though a variety of therapies have taken aim at tau tangles, beta-amyloid plaques and Lewy bodies, among other notorious aggregates, none have been very effective at stopping disease progression.
Rockefeller’s Hermann Steller and his team in the Strang Laboratory of Apoptosis and Cancer Biology have long been focused on understanding how the cell’s protein-degrading machines, called proteasomes, are regulated. His lab discovered that a transporter protein termed PI31 shuttles proteasomes over long distances from the nerve cell body to synapses. When this system fails, synapses become depleted of degradative capacity, and proteins that should have been eliminated accumulate. As a result, synaptic communication breaks down, protein clumps form and neuronal health deteriorates.
Now a new study in Nature Communications, led by researchers from University College London and contributed to by Steller’s lab, has identified mutations in PSMF1, the gene that produces PI31, that cause the protein to malfunction. Moreover, the scientists demonstrated that these mutations cause a spectrum of severe, very early-onset neurological disorders.
A Supplement For Joint Pain Could Accelerate Alzheimer’s Memory Loss
People with Alzheimer’s disease who took the common supplement glucosamine were 25% more likely to die within five years than those who didn’t.
That’s the key finding of a new study that my colleagues and I published in the journal Nature Metabolism.
Glucosamine is a sugar molecule that’s sold over the counter as a remedy for joint pain and arthritis. More than 40 million Americans take it each year.
Biohybrid: The Science biohybrid architecture integrates neurons into its electronics, rather than trying to integrate electronics into the brain
Using hundreds of thousands of neurons anchored to the device, the Science architecture connects to the brain with orders of magnitude more bandwidth than current state-of-the-art devices, while avoiding the damage and limitations of putting wires into a brain.
Human learning of noninvasive brain–computer interfaces via manifold geometry
Busch et al. use nonlinear neural manifolds to help humans gain rapid control over a noninvasive brain–computer interface, allowing them to learn how to play a video game with real-time fMRI neurofeedback from cognitive brain regions.
Biohybrid Brain–Machine Interfaces: The Next Evolution of Human Intelligence
Brain–machine interfaces (BMIs) are no longer just science fiction; they are the gateway to a future where thought itself can interact directly with technology. These systems read the brain’s electrical activity and, in turn, stimulate neurons — forming a two-way communication link between biology and machines.
In just a few decades, BMIs have evolved from laboratory curiosities into one of the fastest-growing frontiers in science and engineering. The possibilities are staggering. In the future, neural interfaces could restore vision to the blind, enable paralyzed individuals to move again, facilitate seamless communication between human brains and artificial intelligence, and ultimately power virtual realities that are indistinguishable from the physical world.
This convergence of biology, computing, and neuroscience marks the dawn of a new era — one where the boundaries between human and machine begin to blur.









